Undetectable Minimal Residual Disease

Patients with chronic lymphocytic leukemia who achieved undetectable minimal residual disease achieved significantly longer PFS than patients with minimal residual disease, according to results of a systematic review and meta-analysis.

ORLANDO — The addition of venetoclax to ibrutinib as a consolidation therapy appeared associated with high rates of undetectable minimal residual disease in bone marrow and complete response within 12 months among patients with high-risk chronic lymphocytic leukemia, according to phase 2 study results presented at ASH Annual Meeting and Exposition.

ORLANDO — A chemoimmunotherapy regimen containing ibrutinib, fludarabine, cyclophosphamide and obinutuzumab resulted in high rates of clinical remission and undetectable minimal residual disease in previously untreated patients with chronic lymphocytic leukemia who harbor IGHV mutations but lack 17p deletions and TP53 mutations, according to data presented at the ASH Annual Meeting and Exposition.

ORLANDO — The combination of acalabrutinib, venetoclax and obinutuzumab demonstrated high rates of complete response and undetectable minimal residual disease in bone marrow among patients with previously untreated chronic lymphocytic leukemia, according to results of a single-arm phase 2 study presented at ASH Annual Meeting and Exposition.